KWB01-A shows inhibitory activities against BRD4 (BD1+BD2) and BRD2 (BD1+BD21).
We expect that KWB01-A as a novel drug candidate having activity against age-related
diseases such as diabetic retinopathy, atherosclerosis, rheumatoid arthritis,
and inflammatory diseases.
KWB04-B shows inhibitory activities against BRD4(BD1+BD2), BRD2 (BD1+BD2).
KWB04-C has BD2-specific inhibitory activity against BRD4(BD2) and BRD2(BD2).